ENDRA Life Sciences (NDRA) Liabilities and Shareholders Equity (2016 - 2026)
ENDRA Life Sciences (NDRA) posted quarterly Liabilities and Shareholders Equity of $3.4 million for Q1 2026, up 8.44% year-over-year from $3.2 million in Q1 2025, and down 10.78% quarter-over-quarter from $3.9 million in Q4 2025.
ENDRA Life Sciences (NDRA) Liabilities and Shareholders Equity (2016 - 2026) Analysis & Trends
ENDRA Life Sciences (NDRA) has reported Liabilities and Shareholders Equity for 11 consecutive years, with $3.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 8.44% year-over-year to $3.4 million; the TTM figure through Mar 2026 stood at $10.6 million (down 26.56% YoY), while the FY2025 annual figure was $3.9 million, up 566.73% from the prior year.
- Liabilities and Shareholders Equity fell to $3.4 million in Q1 2026 per NDRA's latest filing, from $3.9 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $15.3 million in Q2 2022 and bottomed at $229771.0 in Q3 2024.
- Historically, Liabilities and Shareholders Equity has averaged $6.4 million across 5 years, with a median of $6.7 million in 2023.
- Annual changes were most pronounced in 2024 — Liabilities and Shareholders Equity slumped 96.98% — and 2025, when it soared 566.73%.
- ENDRA Life Sciences' Liabilities and Shareholders Equity stood at $9.3 million in 2022, then slipped by 27.17% to $6.8 million in 2023, then tumbled by 91.44% to $578013.0 in 2024, then jumped by 566.73% to $3.9 million in 2025, then declined by 10.78% to $3.4 million in 2026.
- Business Quant data shows NDRA's Liabilities and Shareholders Equity at $3.4 million in Q1 2026, $3.9 million in Q4 2025, and $491363.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.40 Bn | 209.33 Bn | 8.34 Bn | 113.17 Bn |
| 2 | Danaher | 139.94 Bn | 135.59 Bn | 3.61 Bn | 92.37 Bn |
| 3 | Idexx Laboratories | 46.03 Bn | 45.83 Bn | 779.09 Mn | 3.44 Bn |
| 4 | Agilent Technologies | 39.69 Bn | 37.88 Bn | 990.00 Mn | 13.07 Bn |
| 5 | Iqvia Holdings | 39.32 Bn | 37.24 Bn | 1.44 Bn | 29.88 Bn |
| 6 | Natera | 38.47 Bn | 37.37 Bn | 696.04 Mn | 2.61 Bn |
| 7 | Illumina | 29.98 Bn | 28.82 Bn | 770.00 Mn | 6.65 Bn |
| 8 | Mettler Toledo International | 28.57 Bn | 28.52 Bn | 650.22 Mn | 3.67 Bn |
| 9 | Quest Diagnostics | 26.21 Bn | 25.58 Bn | 1.03 Bn | 16.94 Bn |
| 10 | ENDRA Life Sciences | 5.44 Mn | 5.08 Mn | - | 3.44 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.44 Mn |
| Dec 31, 2025 | 3.85 Mn |
| Sep 30, 2025 | 491,363.00 |
| Jun 30, 2025 | 2.81 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Dec 31, 2024 | 578,013.00 |
| Sep 30, 2024 | 229,771.00 |
| Jun 30, 2024 | 10.44 Mn |
| Mar 31, 2024 | 5.06 Mn |
| Dec 31, 2023 | 6.75 Mn |
| Sep 30, 2023 | 7.60 Mn |
| Jun 30, 2023 | 9.24 Mn |
| Mar 31, 2023 | 6.65 Mn |
| Dec 31, 2022 | 9.27 Mn |
| Sep 30, 2022 | 12.34 Mn |
| Jun 30, 2022 | 15.31 Mn |
| Mar 31, 2022 | 10.94 Mn |
| Dec 31, 2021 | 12.87 Mn |
| Sep 30, 2021 | 15.31 Mn |
| Jun 30, 2021 | 17.24 Mn |